N
Nan Lin
Researcher at Harvard University
Publications - 1220
Citations - 65601
Nan Lin is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Breast cancer. The author has an hindex of 105, co-authored 687 publications receiving 54545 citations. Previous affiliations of Nan Lin include University of Michigan & Fujian Medical University.
Papers
More filters
Journal ArticleDOI
An Iteration Algorithm for American Options Pricing Based on Reinforcement Learning
TL;DR: An iteration algorithm for the pricing of American options based on reinforcement learning, where at each iteration, the method approximates the expected discounted payoff of stopping times and produces those closer to optimal.
Journal ArticleDOI
Key phenotypes related to wheat grain yield in a two‐site multi‐cultivar test
TL;DR: In this paper , a two-site multicultivar test in Henan and Anhui in China during the 2016-2017 wheat growing season was conducted to assess the relationships between grain yield and other related phenotypes and reveal the key phenotypes related to grain yield.
Journal ArticleDOI
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer
Romualdo Barroso-Sousa,Ines Vaz-Luis,Ines Vaz-Luis,Antonio Di Meglio,Antonio Di Meglio,Jiani Hu,Tianyu Li,Rebecca Rees,Natalie Faye Sinclair,Lindsey Milisits,Jose Pablo Leone,Michael Constantine,Meredith Faggen,Frederick Briccetti,Caroline Block,Ann H. Partridge,Harold J. Burstein,Adrienne G. Waks,Nabihah Tayob,Lorenzo Trippa,Sara M. Tolaney,Michael J. Hassett,Eric P. Winer,Nan Lin +23 more
TL;DR: In this paper, the safety of omitting corticosteroids after cycle 2 during the paclitaxel portion of the dose-dense (DD) doxorubicin-cyclophosphamide (AC)-paclitaxels regimen was tested.
Journal ArticleDOI
Multi-stimuli-responsive molecular fluorescent probes for bioapplications.
TL;DR: In this paper , the progress of multi-stimuli-responsive probes, including organic molecules and metal complexes, for the detection of various biomarkers for bio-applications is summarized.
Journal ArticleDOI
Abstract P2-13-05: Central nervous system metastases as a site of first recurrence in adjuvant therapy trials of HER2+ early breast cancer (EBC)
Nan Lin,D Lueftner,Adam Brufsky,Sara M. Tolaney,Michelle E. Melisko,Frankie A. Holmes,Ahmad Awada +6 more
TL;DR: The risk of developing a CNS metastasis as the site of first recurrence is generally low; however, it is higher in those with residual disease after neoadjuvant therapy, as well as in pts with hormone receptor positive (HR+) disease.